Bioethics

Bioethics Debt/EBITDA

The Total Debt to EBITDA Ratio of Bioethics (BOTH) as of Oct 21, 2026 is -8.78. In the previous year, Total Debt to EBITDA Ratio was -8.89 — a change of -1.22% (higher).

Debt/EBITDA

-8.78

YoY

-1.22%

Last updated:

Total Debt to EBITDA Ratio of Bioethics is 2023 -8.78 . Total Debt to EBITDA Ratio of Bioethics was 2022 -8.89 . It decreases by -1.22% higher compared to the previous year.

The Bioethics Debt/EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Debt/EBITDA
Date
Debt/EBITDA
Jan 1, 2016
-3.19 USD
Jan 1, 2017
-3.46 USD
Jan 1, 2018
-4.65 USD
Jan 1, 2019
-4.34 USD
Jan 1, 2020
-4.86 USD
Jan 1, 2021
-6.66 USD
Jan 1, 2022
-8.89 USD
Jan 1, 2023
-8.78 USD
The Bioethics Debt/EBITDA history
YEARDebt/EBITDAYoY
-8.78-1.22%
-8.89+33.59%
-6.66+36.92%
-4.86+12.13%
-4.34-6.68%
-4.65+34.10%
-3.46+8.71%
-3.19+122.68%
-1.43+1,079.99%
-0.12—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Bioethics Stock analysis

What does Bioethics do? Bioethics Ltd. is a shell company with no operations or revenue. The company has no full-time employees and is formed to pursue a merger, share exchange, asset acquisition, or similar business combination with another entity. It has not identified any specific target for such a transaction and has not engaged in any substantive discussions with potential partners. The firm remains inactive without generating any income from operations. Bioethics Ltd. does not sell any products or services. It is structured as a vehicle for future business combinations, with no current business activities or revenue streams. The company's purpose is limited to seeking a merger or acquisition target, and it has not yet entered into any agreements or initiated any operational activities. There are no brands, customers, or segments associated with its current status. The firm is headquartered in Ogden, Utah, but this location is not used for any operational purposes. Bioethics Ltd. has no employees, no revenue, and no business activities beyond the formation of the shell company itself. It has not generated any income or engaged in any transactions that would produce revenue. Bioethics is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Bioethics stock

Total Debt to EBITDA Ratio of Bioethics is -8.78 in 2023.

Total Debt to EBITDA Ratio of Bioethics changed from -8.89 to -8.78, representing a -1.22% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Total Debt to EBITDA Ratio Bioethics since 2006 – with annual values, charts, and detailed analysis.

Debt/EBITDA measures total debt relative to earnings before interest, taxes, depreciation, and amortization. It indicates the years needed to repay all debt from EBITDA.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Total Debt to EBITDA Ratio's Bioethics with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Bioethics

All Key Metrics — Bioethics